Edmon R. Jennings
Nessuna posizione attualmente
Profilo
Edmon R.
Jennings served as VP-Corporate Development, Sales & Marketing at Genentech, Inc. from 1985 to 2000.
He also worked as President, Chief Executive Officer & Director at Angiogenix, Inc. from 2003 to 2008, and as Director at Monogram Biosciences, Inc. from 2001 to 2009.
Additionally, he was the Chief Commercialization Officer at Cassava Sciences, Inc. from 2000 to 2003.
Jennings served as an Independent Director at Versartis, Inc. from 2013 to 2018.
He also worked as Manager-Western Region Sales at Bristol Myers Squibb Co. Furthermore, Jennings earned an undergraduate degree from the University of Michigan.
Precedenti posizioni note di Edmon R. Jennings
| Società | Posizione | Fine |
|---|---|---|
Versartis, Inc.
 Versartis, Inc. Pharmaceuticals: MajorHealth Technology Versartis, Inc. is an endocrine-focused biopharmaceutical company, which engages in the research and development of pharmaceutical products. Its portfolio includes Somavartan and XTEN TEchnology which target the endocrine disorders and growth hormone deficiencies. The company was founded by Jeffrey L. Cleland, Mark de Boer, Willem Stemmer, Volker Schellenberger, and Joshua Silverman on December 10, 2008 and is headquartered in Menlo Park, CA. | Presidente | 01/12/2013 |
Monogram Biosciences, Inc.
 Monogram Biosciences, Inc. Miscellaneous Commercial ServicesCommercial Services Monogram Biosciences, Inc. develops and commercializes diagnostic products for the treatment of human immunodeficiency virus (HIV) infection, hepatitis C virus (HCV) infection, and other viral illnesses, as well as cancer and other diseases. It offers HIV tests, including genotypic, phenotypic, tropism, and combined phenotype and genotype assays, suppression management and viral load testing, HCV assays and oncology tests. The company was founded in 1995 and is headquartered in South San Francisco, CA. | Direttore/Membro del Consiglio | 04/06/2009 |
Angiogenix, Inc.
 Angiogenix, Inc. Pharmaceuticals: MajorHealth Technology Angiogenix, Inc. develops therapeutic solutions for chronic vascular disease. Its products help the body produce new blood vessels to increase blood flow. The company's product ACCLAIM treats chronic ischemia (lack of oxygen in the heart muscle). Angx1039 is being developed to treat peripheral vascular disease (a narrowing of the vessels carrying blood to the legs, arms and internal organs) and Angx3227 targets sickle cell disease (an inherited disorder that affects the shape of red blood cells). Its fourth product, Vasotrophin increases blood vessel density. The company is headquartered at Burlingame, CA | Amministratore Delegato | 06/03/2008 |
| CASSAVA SCIENCES, INC. | Corporate Officer/Principal | 01/06/2003 |
Genentech, Inc.
 Genentech, Inc. BiotechnologyHealth Technology Genentech, Inc. develops, manufactures and markets pharmaceutical products for life-threatening medical conditions. It studies various areas including oncology, immunology, neuroscience, ophthalmic diseases, microbial pathogenesis, metabolic diseases, cardiovascular diseases, and opportunistic areas. The company was founded by Herb W. Boyer and Robert A. Swanson in 1976 and is headquartered in South San Francisco, CA. | Vendite & Marketing | 01/01/2000 |
Formazione di Edmon R. Jennings
| University of Michigan | Undergraduate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Società quotate in Borsa | 2 |
|---|---|
| CASSAVA SCIENCES, INC. | Health Technology |
| BRISTOL-MYERS SQUIBB COMPANY | Health Technology |
| Aziende private | 5 |
|---|---|
Monogram Biosciences, Inc.
Monogram Biosciences, Inc. Miscellaneous Commercial ServicesCommercial Services Monogram Biosciences, Inc. develops and commercializes diagnostic products for the treatment of human immunodeficiency virus (HIV) infection, hepatitis C virus (HCV) infection, and other viral illnesses, as well as cancer and other diseases. It offers HIV tests, including genotypic, phenotypic, tropism, and combined phenotype and genotype assays, suppression management and viral load testing, HCV assays and oncology tests. The company was founded in 1995 and is headquartered in South San Francisco, CA. | Commercial Services |
Angiogenix, Inc.
Angiogenix, Inc. Pharmaceuticals: MajorHealth Technology Angiogenix, Inc. develops therapeutic solutions for chronic vascular disease. Its products help the body produce new blood vessels to increase blood flow. The company's product ACCLAIM treats chronic ischemia (lack of oxygen in the heart muscle). Angx1039 is being developed to treat peripheral vascular disease (a narrowing of the vessels carrying blood to the legs, arms and internal organs) and Angx3227 targets sickle cell disease (an inherited disorder that affects the shape of red blood cells). Its fourth product, Vasotrophin increases blood vessel density. The company is headquartered at Burlingame, CA | Health Technology |
Genentech, Inc.
Genentech, Inc. BiotechnologyHealth Technology Genentech, Inc. develops, manufactures and markets pharmaceutical products for life-threatening medical conditions. It studies various areas including oncology, immunology, neuroscience, ophthalmic diseases, microbial pathogenesis, metabolic diseases, cardiovascular diseases, and opportunistic areas. The company was founded by Herb W. Boyer and Robert A. Swanson in 1976 and is headquartered in South San Francisco, CA. | Health Technology |
TRF Pharma, Inc.
 TRF Pharma, Inc. Pharmaceuticals: MajorHealth Technology TRF Pharma, Inc. develops pharmaceutical products. It specializes in the fields of hematology and oncology. The firm's services include developing therapies to treat diseases related to aberrant cell adhesion and endothelial walls. The company was founded by Stephen H. Embury and Neil Matsui in 2002 and is headquartered in Burlingame, CA. | Health Technology |
Versartis, Inc.
Versartis, Inc. Pharmaceuticals: MajorHealth Technology Versartis, Inc. is an endocrine-focused biopharmaceutical company, which engages in the research and development of pharmaceutical products. Its portfolio includes Somavartan and XTEN TEchnology which target the endocrine disorders and growth hormone deficiencies. The company was founded by Jeffrey L. Cleland, Mark de Boer, Willem Stemmer, Volker Schellenberger, and Joshua Silverman on December 10, 2008 and is headquartered in Menlo Park, CA. | Health Technology |
- Borsa valori
- Insiders
- Edmon R. Jennings
